Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Nuance Communications Inc. (NUAN), American Capital Agency Corp. (AGNC): What This Top-Earning Billionaire Has Been Buying

Page 1 of 2

Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a bright light on smart stock picks.

Today, let’s look at Moore Capital Management, managed by billionaire Louis Moore Bacon. Bacon is known for employing a global macroeconomic focus in his investing, and has been among the top 20 money earners since the 1990s, per Bacon’s fund has turned in some spectacular performances, but also some lackluster ones, and, after poor results in 2011, he returned $2 billion to shareholders, citing the fund’s size as an obstacle. Still, Bacon seems to have solid investing chops, with his flagship fund reportedly averaging nearly 19% in annual gains since its inception in 1989 (as of 2012).

The company’s reportable stock portfolio totaled $4.2 billion in value as of June 30, 2013.

Interesting developments
So, what does Moore’s latest quarterly 13F filing tell us? Here are a few interesting details:

MOORE GLOBAL INVESTMENTSThe biggest new holdings are calls options on the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) and the PowerShares QQQ Trust, Series 1 (ETF) (NASDAQ:QQQ). Other new holdings of interest include Nuance Communications Inc. (NASDAQ:NUAN) and American Capital Agency Corp. (NASDAQ:AGNC) . Nuance is a major developer of speech-recognition software, with its technology housed in many Apple Inc. (NASDAQ:AAPL) devices (think “Siri”). (Thus, its fortunes are somewhat tied to Apple’s.) While some see the stock as undervalued now, others are bailing, not liking its recent performance or the CEO’s compensation package. The company’s future is quite uncertain, but bulls see potential, such as in the health-care industry’s looming deadline to update its coding system. Nuance is digging in to the health-care industry, fitting its technology with the Epic software used by many in health care. Nuance Communications Inc. (NASDAQ:NUAN) is also working with Echo Nest to develop more music and entertainment offerings.

American Capital Agency Corp. (NASDAQ:AGNC) is a mortgage REIT with a tantalizing dividend yield recently above 17% — though that reflects a 16% dividend cut earlier this year. American Capital’s stock has been volatile, shedding about 25% over the past year, but still averaging 29% annual gains over the past five. The company’s CEO is well-respected, but some worry about rising interest rates, the easing of quantitative easing, and mortgage REITs losing a valuable tax advantage. The company has been moving more into 15-year mortgages, and decreasing its focus on 30-year ones. The shorter loans are less volatile, but they also offer lower yields.

Among holdings in which Moore Capital Management increased its stake was Synovus Financial Corp. (NYSE:SNV). Georgia-based Synovus recently repaid its $968 million TARP debt, in part by issuing more stock. Its credit quality has been improving, and it has been posting strong return-on-equity (ROE) numbers. It just reported its fourth-profitable quarter in a row, too. Management aims to cut at least $30 million in costs this year, and has cut much more in recent years. Analysts at Zacks upgraded Synovus in July to a Strong Buy, noting, “A decline in non-interest expense, improvement in credit quality and strong capital ratios depict the scope of sustainable profitability in the forthcoming quarters.” Analysts at Drexel Hamilton downgraded the stock in August, though, on valuation concerns. The stock yields 1.2%.

Moore Capital Management reduced its stake in lots of companies, including Amarin Corporation plc (ADR) (NASDAQ:AMRN), a late-stage cardiovascular-focused biotech enterprise, with a promising (and FDA-approved) drug to lower triglycerides — its fish-oil-based Vascepa. It needs a big partner for Vascepa, though, and one likely suitor bought a competitor instead. Amarin recently collected its 30th patent for Vascepa, upping its ultimate commercial potential — though some see that potential significantly threatened by competition. Bears also see fish oil as a controversial and, therefore, problematic offering.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!